AdnaGen and OncoVista Innovative Therapies, Inc., Announce the Issuance in the U.S. of a Key Patent Related to Technology for the Detection and Analysis of Circulating Tumor Cells

LANGENHAGEN, Germany & SAN ANTONIO--(BUSINESS WIRE)--AdnaGen AG, a molecular diagnostics company, and subsidiary of OncoVista Inc., (OTCBB:OVIT.OB), focused on the detection and molecular analysis of tumor cells from the blood of cancer patients has been issued a core-patent by the United States Patent and Trademark Office. United States Patent 7,507,528 issued Mar 24, 2009, and titled “Method and Diagnosis Kit for Selecting and or Qualitative and/or Quantitative Detection of Cells”, claims broad methods for the identification and molecular analysis of rare cells, particularly circulating tumor cells, in the presence of a large excess of unrelated cells.